ACC Asia 2023 to bring together experts to improve cardiovascular care

Bris­tol My­ers Squibb dis­closed Thurs­day at its R&D Day that it cut six pro­grams, in­clud­ing mid-stage drug can­di­dates for NASH and sol­id tu­mors. The New

The FDA this month pub­lished a flur­ry of Fed­er­al Reg­is­ter no­tices ex­plain­ing in­stances when pri­or­i­ty re­view vouch­ers (PRVs) have been re­deemed un­der the rare pe­di­atric